Next-generation of Prostate Cancer Care: Australia Leading the World

Saving Lives with Lutetium-177: Australia Leading the World with PSMA PET/CT and Radioligand Therapy

Professor Michael Hofman is a nuclear medicine physician at the Peter MacCallum Cancer Centre in Melbourne, Australia's only public hospital dedicated to cancer treatment, research and education. He has a co-appointment at the University of Melbourne and previously completed a fellowship at Guy's & St Thomas' hospital in London. Professor Hofman is Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at Peter Mac. His research is focussed on novel radionuclides for imaging and therapy, including pre-clinical, and phase 1 to 3 clinical trials. He led landmark clinical trials of PSMA imaging and therapy including the ProPSMA (Lancet ‘20, ACTA Trial of the Year) and TheraP (Lancet ‘21). He has authored or co-authored over 220 peer-reviewed articles and is an inaugural scientific member of the Australasian Radiopharmaceutical Trials Network (ARTnet). He is an editor for several international journals including the Journal of Nuclear Medicine, European Urology and Cancer Imaging.